CRP Clinical Trials

3 recruiting

Frequently Asked Questions

Common questions about CRP clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 50 trials

Recruiting
Phase 1Phase 2

Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617

Prostate CancerNeoplasmsNeoplasms by Site+7 more
Pathos AI, Inc.252 enrolled24 locationsNCT06785636
Recruiting
Phase 1

A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer

Metastatic Prostate Cancer (mCRPC)
Novartis Pharmaceuticals15 enrolled4 locationsNCT07174063
Recruiting
Phase 1Phase 2

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
Novartis Pharmaceuticals123 enrolled6 locationsNCT07226986
Recruiting
Phase 3

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms
Merck Sharp & Dohme LLC1,314 enrolled322 locationsNCT06136650
Recruiting
Phase 1Phase 2

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

Castration-Resistant Prostate Cancer (CRPC)
Radiopharm Theranostics, Ltd61 enrolled4 locationsNCT07189871
Recruiting
Phase 1

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Breast CancerCervical CancerColon Cancer+4 more
Orano Med LLC48 enrolled4 locationsNCT05283330
Recruiting
Phase 1

Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer

Metastatic Castration-resistant Prostate Cancer (CRPC)
TechnoGenesys, Inc.40 enrolled1 locationNCT06705686
Recruiting

Peripersonal Space Representation in Upper Limb Segmental Exclusion

Segmental Exclusion SyndromeComplex Regional Pain Syndrome (CRPS)Upper Limb Neglect (Peripheral)
Union de Gestion des Etablissements des Caisses d'Assurance Maladie - Nord Est60 enrolled1 locationNCT07349173
Recruiting
Not Applicable

Perineural Incobotulinumtoxin-A for Complex Regional Pain Syndrome - An Open-label Feasibility Study

CRPS (Complex Regional Pain Syndromes)CRPS (Complex Regional Pain Syndrome) Type ICRPS Type II
Bo Biering-Soerensen20 enrolled1 locationNCT07473635
Recruiting
Not Applicable

CRP Point-of-care Testing Trajectory, a Predictive Factor for Anastomotic Leak in Elective Colorectal Surgery

Colorectal SurgeryAnastomotic LeakEnhanced Recovery+2 more
Centre Hospitalier Universitaire, Amiens500 enrolled1 locationNCT07464600
Recruiting
Phase 3

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Pfizer600 enrolled235 locationsNCT06551324
Recruiting
Phase 2

SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC

Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)
Fudan University66 enrolled3 locationsNCT07451795
Recruiting
Phase 1Phase 2

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Prostate CancerMetastatic Castration-resistant Prostate CancerUrogenital Neoplasms+3 more
Blue Earth Therapeutics Ltd82 enrolled19 locationsNCT05413850
Recruiting
Phase 1

Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Metastatic Castrate Resistant Prostate Cancer (mCRPC)Prostate Cancer (CRPC)
ARTBIO Inc.80 enrolled3 locationsNCT07214961
Recruiting
Not Applicable

Intermittent Dosing of Dorsal Root Ganglion Stimulation as an Alternate Paradigm to Continuous Low-Frequency Therapy

CRPS (Complex Regional Pain Syndromes)
Rush University Medical Center30 enrolled1 locationNCT04909138
Recruiting
Phase 1

Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies

Advanced Malignancies With Homologous Recombination Deficiency (HRD) (Breast, Ovarian, mCRPC, Brain Metastases)
Duke Street Bio Ltd90 enrolled13 locationsNCT06458712
Recruiting
Phase 1Phase 2

A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors

Ovarian CarcinomaNSCLCSCLC+5 more
Jacobio Pharmaceuticals Co., Ltd.152 enrolled1 locationNCT04686682
Recruiting
Phase 1

Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer (Adenocarcinoma)mCRPC (Metastatic Castration-resistant Prostate Cancer)
Acerand Therapeutics (Hong Kong) Limited67 enrolled8 locationsNCT06801236
Recruiting
Not Applicable

Four-Timepoint Multi-tracer PET Imaging to Characterize Metastatic prOstate Cancer Heterogeneity

mCRPC (Metastatic Castration-resistant Prostate Cancer)
Frederic Pouliot45 enrolled1 locationNCT07302763
Recruiting
Not Applicable

CRP and Patient Information Leaflets to Optimise Antibiotic Treatments for Adults With Respiratory Tract Infections in Primary Care in Kyrgyzstan

InflammationRespiratory Tract Infection BacterialRespiratory Tract Infection Viral+2 more
Rigshospitalet, Denmark1,050 enrolled2 locationsNCT07261969